Primary liver cancers are highly malignant tumors in human and their incidences are rising in the United States. The overall survival of patients with liver cancer is grim and currently no efficient chemoprevention is available. On the basis of our published and ongoing studies, we hypothesize that the EP1 receptor plays a key role in prostaglandin-induced hepatic carcinogenesis and that inhibition of EP1 in combination with the multikinase inhibitor, sorafenib, may represent a novel and safe approach for effective chemoprevention. This hypothesis will be examined in the two specific aims using complementary animal models of hepatic carcinogenesis.
Aim 1 will evaluate the combination effect of EP1 inhibition and sorafenib on the development of hepatocellular cancer induced by the hepatic carcinogen, diethylnitrosamine.
Aim 2 will examine the combination effect of EP1 inhibition and sorafenib on the development of intrahepatic cholangiocellular carcinoma induced by Pten/Smad4 disruption. The proposed studies are expected to provide important implications for future chemoprevention of human liver cancer.
Primary liver cancers are highly malignant neoplasms in human and currently there is no effective chemoprevention. Recent studies from our lab have shown that the prostaglandin receptor, EP1, plays an important role in liver carcinogenesis. The current proposal will utilize complementary animal models of hepatic carcinogenesis to evaluate the effect of EP1 inhibition in combination with the multikinase inhibitor, sorafenib, on liver cancer development. The proposed studies will likely devise a new strategy for effective chemoprevention of human liver cancers.
| Lu, D; Han, C; Wu, T (2012) Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/?-catenin signaling axis. Oncogene 31:842-57 |
| Lu, Dongdong; Han, Chang; Wu, Tong (2011) Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression. Gastroenterology 140:2084-94 |
| Han, Chang; Bowen, William C; Li, Guiying et al. (2010) Cytosolic phospholipase A2alpha and peroxisome proliferator-activated receptor gamma signaling pathway counteracts transforming growth factor beta-mediated inhibition of primary and transformed hepatocyte growth. Hepatology 52:644-55 |
